← All trials
NCT06143787
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 7, 2023
- Primary completion
- Jun 27, 2024
- Completion date
- Jun 27, 2024
- First posted
- Nov 22, 2023
- Last posted
- Nov 22, 2023
- Enrollment
- 280
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hyloris Developments SALead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.